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Background: The association of inflammatory factors and the aqueous flare value with macular edema in central
retinal vein occlusion (CRVO) patients remains unclear. We investigated the relations between the aqueous flare value
and vitreous levels of vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule-1 (sICAM-1),
and interleukin-6 (IL-6) in patients with CRVO and macular edema or patients with idiopathic macular hole (MH).
Methods: In 38 patients who underwent unilateral vitrectomy (21 CRVO patients and 17 MH patients), vitreous
samples were obtained during vitrectomy to measure VEGF, sICAM-1, and IL-6. Retinal ischemia was evaluated
from capillary non-perfusion on fluorescein angiography, and the CRVO patients were classified into nonischemic
or ischemic groups. Aqueous flare values were measured with a laser flare meter and macular edema was examined
by optical coherence tomography.
Results: The median aqueous flare value increased significantly across the three groups (MH group < nonischemic
CRVO group < ischemic CRVO group). There was a significant correlation between the flare value and vitreous levels of
VEGF, sICAM-1, and IL-6 in the CRVO group. The flare value was also significantly correlated with the severity of macular
edema in the CRVO group.
Conclusions: Inflammation and/or ischemia may increase vascular permeability and disrupt the blood-aqueous barrier
by increasing levels of inflammatory factors in patients with CRVO and macular edema.Background
Central retinal vein occlusion (CRVO) is frequently asso-
ciated with macular edema, which is the chief cause of
visual impairment in these patients. Intravitreal injection
of antibodies targeting vascular endothelial growth factor
(VEGF), such as bevacizumab or ranibizumab, has been
reported to improve macular edema in patients with
CRVO [1,2]. However, some patients have persistent
macular edema despite treatment with these antibodies
[3,4], suggesting that factors other than VEGF may also
contribute to macular edema. We recently reported
that vitreous fluid levels of inflammatory factors were
significantly correlated with the severity of macular edema
in CRVO patients [5,6], suggesting that inflammation is
important in the development of macular edema. This* Correspondence: noma-hide@umin.ac.jp
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reproduction in any medium, provided the oris supported by the Standard Care vs Corticosteroid for
Retinal Vein Occlusion (SCORE) study, which showed
that intravitreal triamcinolone acetonide improved visual
acuity and macular edema in CRVO patients [7]. More-
over, vitreous fluid levels of inflammatory factors are
reported to be high in ischemic CRVO [5,6], although
some patients with nonischemic CRVO have increased
levels of inflammatory factors, suggesting that inflammation
may also promote macular edema in nonischemic CRVO.
The aqueous flare value is reported to be significantly
higher in patients with retinal vein occlusion (RVO) than
in normal controls [8,9], suggesting that an increased
flare value reflects disruption of the blood-retinal barrier
and blood-aqueous barrier by inflammation. However, the
association of inflammatory factors and the aqueous flare
value with macular edema in CRVO patients remains
unclear. Accordingly, we investigated the relation between
macular edema and inflammatory parameters (flare valuetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical and laboratory characteristics of the
CRVO patients and MH patients
CRVO group MH group P value
Number† 21 17
Gender (Female/male) 10/11 10/7 0.718
Age (yr) 71.2 ± 6.9‡ 68.1 ± 4.9‡ 0.128
Blood pressure (mmHg)
Systolic 139 ± 18‡ 116 ± 13‡ <0.001
Diastolic 78 ± 9‡ 72 ± 8‡ 0.058
Hypertension 12 2 0.004
Hyperlipidemia 7 3 0.275
Duration of CRVO (months) 5.8 ± 2.8‡ - -
†Number of patients with data.
‡Mean ± standard deviation (SD).
CRVO = central retinal vein occlusion; MH =macular hole.
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This study was performed in accordance with the Helsinki
Declaration of 1975 (1983 revision). The institutional
review boards of Tokyo Women’s Medical University
approved the protocol for collection and testing of vitreous
fluid samples. Undiluted vitreous fluid samples were
harvested at the start of vitrectomy after written informed
consent was obtained from each subject following an
explanation of the purpose and potential adverse effects
of the procedure. This was a retrospective case control
study of 38 Japanese patients who underwent vitrectomy
in one eye (21 with CRVO and 17 with idiopathic macular
hole (MH) to treat macular edema. Consecutive patients
with CRVO who presented to the hospital of Tokyo
Women’s Medical University between June 2007 and
March 2011 were screened according to the criteria set
out below and vitreous fluid samples were obtained
from the 21 patients who were enrolled. The indication
for pars plana vitrectomy was relief of vitreomacular
traction in order to improve macular edema caused by
CRVO. The inclusion criteria were (1) patients scheduled
for pars plana vitrectomy to treat macular edema secondary
to CRVO (including patients who had received retinal
photocoagulation) and (2) patients with a best-corrected
visual acuity of worse than 20/50 before surgery. Exclusion
criteria were (1) previous ocular surgery or intravitreous
injection of anti-VEGF agents or triamcinolone acetonide,
(2) diabetes mellitus with diabetic retinopathy, (3) iris
rubeosis, and (4) a history of ocular inflammation or
vitreoretinal disease. Vitreous fluid samples were also
obtained from 17 patients with nonischemic ocular disease
(MH) as a control group (MH group). None of the patients
in the MH group had proliferative vitreoretinopathy.
The CRVO group (10 women and 11 men) was aged
71.2 ± 6.9 years (mean ± SD), while the MH group (10
women and 7 men) was aged 68.1 ± 4.9 years (Table 1).
The mean duration of CRVO was 5.8 ± 2.8 months
(range: 2 – 12 months) (Table 1). This report covers our
recent work on the relationship between cytokines and
the pathogenesis of CRVO. Therefore, the present study
population partially overlaps subjects reported in previous
papers [5,6,10]. Pars plana vitrectomy was performed
at Tokyo Women’s Medical University. A diagnosis of
hypertension or hyperlipidemia was based on data from
the medical records. Before surgery, panretinal photo-
coagulation was done in 4 patients (4 eyes) to prevent
neovascular glaucoma (mean: 1,039 shots; range: 790 to
1,624 shots). Hypertension was defined as current treat-
ment with antihypertensive drugs or a blood pressure >
140/90 mmHg [11]. Hyperlipidemia was defined ascurrent treatment with lipid-lowering agents or a total
cholesterol level > 240 mg/dl. Twelve of the 21 CRVO
patients (57%) had hypertension (Table 1). Seven of the
21 CRVO patients (33%) had hyperlipidemia (Table 1).
Fundus examination
The fundus was examined preoperatively by biomicro-
scopy with a fundus contact lens and by standard fundus
color photography. In addition, fluorescein angiography
was performed with a Topcon TRC-50EX fundus camera,
an image-net system (Tokyo Optical Co. Ltd., Japan), and
a preset lens with a slit-lamp.
Preoperative fundus findings were recorded for each
subject. A masked grader independently assessed retinal
perfusion status or ischemic retinal vascular occlusion
by examination of fluorescein angiograms. The ischemic
area of the retina was measured with the public domain
Scion Image program, as reported previously [5,6]. On a
digital fundus photograph, the disk area was outlined
with a cursor and then measured, as was the non-perfused
area. If the nonperfused area divided by the disc area
gave a value of 10 or more, this was defined as indicating
the presence of retinal ischemia [12-14]. Sites of retinal
photocoagulation were excluded when calculating the
nonperfused area. The 21 CRVO patients included 15
patients with retinal ischemia (87.7 ± 26.6 disc areas),
who were 9 women and 6 men aged 71.6 ± 6.9 years. The
other 6 patients without retinal ischemia (3.8 ± 3.2 disc
areas) comprised 1 woman and 5 men aged 70.3 ± 7.3 years.
Optical coherence tomography (OCT) was performed
in each subject within 1 week before vitrectomy, employing
an instrument from Zeiss-Humphrey Ophthalmic Systems
(Stratus model 3000; Carl Zeiss, Dublin, CA, USA).
The fundus was scanned with the measuring beam focused
on horizontal and vertical planes crossing the center of the
fovea, which was located by examination of the fundus
photograph and by each patient’s fixation. Cross-sectional
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who continued each examination until highly reproducible
scans were obtained. The thickness of the central fovea
was defined as the distance between the inner limiting
membrane and the retinal pigment epithelium (including
any serous retinal detachment), and was automatically
measured by computer software. The thickness of the
neurosensory retina was defined as the distance between
the inner and outer neurosensory retinal surfaces [15],
and the severity of macular edema was graded from the
measured retinal thickness. The average preoperative
retinal thickness was 670 ± 155 μm, with a range of
434 to 976 μm.
Measurement of aqueous flare
The aqueous flare was measured with a laser flare meter
(FC-600, Kowa Co. Ltd., Tokyo, Japan), as described
previously [16]. The sensitivity and reproducibility of
this method have been confirmed by a number of studies
[8,9,16]. Measurements were performed within 1 week
before treatment. Flare values and cell counts were mea-
sured at 30 minutes after dilation of the pupil with 0.5%
tropicamide and 5% phenylephrine hydrochloride. Two
different examiners obtained five measurements from
each eye and the results were averaged after excluding
all measurements with artefacts.
Sample collection
Samples of undiluted vitreous fluid (500 – 1,000 μl) were
collected at the start of vitrectomy by aspiration into a 1 ml
syringe attached to the vitreous cutter before commencing
the intravitreal infusion of balanced salt solution. The
vitreous samples were immediately transferred into sterile
tubes and were rapidly frozen at −80°C.
Measurement of inflammatory factors
The levels of VEGF, sICAM-1, and IL-6 were measured
in vitreous samples from the same eye and in plasma
samples by enzyme-linked immunosorbent assay using
kits for human VEGF, sICAM-1, and IL-6 (VEGF and
IL-6: R&D Systems, Minneapolis, MN; sICAM-1: Bender
Med Systems, Burlingame, CA, USA) [5,6]. The VEGF kit
detected two of the four VEGF isoforms, which were
VEGF121 and VEGF165. The levels of these factors in the
vitreous fluid samples and plasma were within the detec-
tion ranges of the assays, with the minimum detectable
concentration being 15.6 pg/ml for VEGF (intra-assay CV
5.5%, inter-assay CV 6.7%), 3.3 ng/ml for sICAM-1 (intra-
assay CV 5.4%, inter-assay CV 7.7%), and 0.156 pg/ml for
IL-6 (intra-assay CV 5.5%, inter-assay CV 6.8%).
Statistical analysis
All analyses were performed with SAS System 9.3 software
(SAS Institute Inc., Cary, North Carolina, USA). Data arepresented as the mean ± SD or as the median with the
interquartile range or frequency. Student’s t-test was
employed to compare normally distributed unpaired
continuous variables between the two groups and the
Mann-Whitney U test was used for variables with a
skewed distribution. Probability values for trends among
the three groups were calculated with a linear regression
model. To examine the relations among vitreous levels
of VEGF, sICAM-1, or IL-6, the aqueous flare value,
and the severity of macular edema, Spearman’s rank-order
correlation coefficients and a multiple linear regression
model were used. Two-tailed p values of less than 0.05
were considered to indicate a statistically significant
difference.Results
The aqueous flare value (median [interquartile range])
showed a significant increase across the three groups
(MH group: 5.3 photon counts/ms [4.3-6.2] < nonischemic
CRVO group: 9.3 photon counts/ms [8.7-10.5] < ischemic
CRVO group: 25.1 photon counts/ms [20.7-34.6]) (Ptrend <
0.001; Table 2). The vitreous fluid level of VEGF also
showed a significant increase across the three groups
(MH group: 15.6 pg/ml [15.6-15.6] < nonischemic CRVO
group: 83.3 pg/ml [15.6-143] < ischemic CRVO group:
1050 pg/ml [335-3717]) (Ptrend < 0.001; Table 2). Likewise,
the vitreous fluid level of sICAM-1 showed a signifi-
cant increase across the three groups (MH group:
4.1 ng/ml [3.6-5.8] < nonischemic CRVO group: 8.4 ng/ml
[6.2-9.4] < ischemic CRVO group: 19.8 ng/ml [12.7-37.0])
(Ptrend < 0.001; Table 2). Moreover, the vitreous fluid level
of IL-6 showed a significant increase across the three
groups (MH group: 1.06 ng/ml [0.85-1.52] < nonischemic
CRVO group: 11.5 ng/ml [8.0-42.8] < ischemic CRVO
group: 51.2 ng/ml [22.2-104.8]) (Ptrend < 0.001; Table 2).
There was a significant correlation between the aque-
ous flare value and the vitreous fluid levels of VEGF,
sICAM-1, and IL-6 in the CRVO group (ρ = 0.73, P = 0.001,
ρ = 0.66, P = 0.003, and ρ = 0.63, P = 0.005, respectively)
(Table 3). Furthermore, to clarify which factor (VEGF,
sICAM1, or IL6) was most closely correlated with the
aqueous flare value, multiple linear regression analysis
with stepwise selection of variables was performed.
This analysis showed that sICAM-1 was most strongly
correlated with the aqueous flare value. The aqueous
flare value was also significantly correlated with the
severity of macular edema in the CRVO group (ρ = 0.54,
P = 0.015) (Table 3).
Vitreous fluid levels of VEGF, sICAM-1, and IL-6 were
also significantly correlated with the severity of macular
edema in the CRVO group (ρ = 0.49, P = 0.029, ρ = 0.66,
P = 0.003, and ρ = 0.61, P = 0.006, respectively) (Figures 1A-
C). In addition, to clarify which factor (VEGF, sICAM1,
Table 2 Aqueous flare and vitreous levels of various factors in the control, nonischemic CRVO, and ischemic
CRVO groups
Variable Control Nonischemic Ischemic P value for trend test
Aqueous flare value 5.3 [4.3-6.2] 9.3 [8.3-10.5] 25.1 [20.7-34.6] <0.001
(photon counts/ms)
VEGF (pg/ml) 15.6 [15.6-15.6] 83.3 [15.6-143] 1050 [335-3717] <0.001
sICAM-1 (ng/ml) 4.1 [3.6-5.8] 8.4 [6.2-9.4] 19.8 [12.7-37.0] <0.001
IL-6 (pg/ml) 1.06 [0.85-1.52] 11.5 [8.0-42.8] 51.2 [22.2-104.8] <0.001
CRVO = central retinal vein occlusion; VEGF = vascular endothelial growth factor; sICAM-1 = soluble intercellular adhesion molecule 1; IL-6 = interleukin-6.
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macular edema, multiple linear regression analysis with
stepwise selection of variables was performed. It was
found that sICAM-1 was most strongly correlated with
the severity of macular edema.
In the CRVO group, there were no significant correlations
between the aqueous flare value and age, hypertension,
hyperlipidemia, or the duration of CRVO (data not shown,
P = 0.680, P = 0.274, P = 0.918, and P = 0.450, respectively).
There were also no significant correlations between the
vitreous fluid level of VEGF and these variables (data
not shown, P = 0.593, P = 0.413, P = 0.575, and P = 0.068,
respectively). Likewise, there were no significant corre-
lations between the vitreous fluid level of sICAM-1
and these variables (data not shown, P = 0.572, P = 0.644,
P = 0.073, and P = 0.090, respectively), as well as no signifi-
cant correlations between the vitreous fluid level of IL-6
and these variables (data not shown, P = 0.819, P = 0.831,
P = 0.550, and P = 0.312, respectively).Discussion
The present study revealed that the protein concentration
in aqueous humor (aqueous flare value) was significantly
higher in the CRVO group than in the MH group, as
well as showing a significant difference between the
ischemic and nonischemic CRVO groups. In addition,
vitreous fluid levels of inflammatory factors (VEGF,
sICAM-1, and IL-6) showed a significant increase across
the three groups from the MH group to the ischemic
CRVO group. Furthermore, there was a significant cor-
relation between the aqueous flare value and vitreousTable 3 Correlation of aqueous flare values with levels of
vitreous factors and retinal thickness
ρ P value
VEGF (pg/ml) 0.73 0.001
sICAM-1 (ng/ml) 0.66 0.003
IL-6 (pg/ml) 0.63 0.005
Macular retinal thickness (μm) 0.54 0.015
VEGF = vascular endothelial growth factor; sICAM-1 = soluble intercellular adhe-
sion molecule 1; IL-6 = interleukin-6; γ = ρ = correlation coefficient.fluid levels of these inflammatory factors in the CRVO
group. Therefore, the increase of the flare value in
CRVO may be related to increased production of in-
flammatory factors (such as VEGF, sICAM-1, and IL-6)
due to inflammation and/or ischemia. Miyake et al. [8]
performed anterior chamber and vitreous fluorophoto-
metry, demonstrating increased fluorescein concentrations
in the anterior chamber and the posterior vitreous of
patients with RVO, whereas fluorescein levels in the
middle vitreous were low or normal. They concluded that
the increase of the aqueous flare mainly reflects disruption
of the blood-aqueous barrier in RVO patients and that
this barrier may be damaged in the anterior segment.
Furthermore, Virdi et al. [17] found an increase of
fluorescein in the aqueous humor and leakage from
vessels of the iris on fluorescein angiography in patients
who had major branch RVO or CRVO without any evident
iridic abnormalities or rubeosis. Fluorescein leakage from
the iridic vessels has also been identified in monkeys
with experimental RVO before the onset of iridic neo-
vascularisation [17]. These reports and our results suggest
that the aqueous flare value may be increased by leakage
of protein from the iridic vessels due to disruption of
the blood-aqueous barrier by inflammatory factors such
as VEGF, sICAM-1, and IL-6.
In the present study, we detected a significant correl-
ation between the aqueous flare value and the severity of
macular edema in our CRVO patients (Table 3). This
finding is supported by the report that cystoid macular
edema is associated with more severe blood-aqueous
barrier disruption [18], and also suggests that macular
edema in CRVO patients may be related to inflammation
and/or ischemia. There was also significant correlation
between the severity of macular edema and the vitreous
fluid levels of VEGF, sICAM-1, and IL-6 in our CRVO
patients. Therefore, the correlation between the aqueous
flare value and the severity of macular edema in the
CRVO group points to a role of inflammatory factors
(VEGF, sICAM-1, and IL-6) in the development of
macular edema by increasing vascular permeability and/or
diapedesis of leucocytes. Thus, these findings suggest
that inflammation and/or ischemia may promote vascular
permeability and damage the blood-aqueous barrier by
Figure 1 Correlation between the severity of macular edema
and the vitreous fluid levels of vascular endothelial growth factor
(VEGF), soluble intercellular adhesion molecule-1 (sICAM-1), and
interleukin-6 (IL-6). In the CRVO group, vitreous levels of VEGF (A),
sICAM-1 (B), and IL-6 (C) were significantly correlated with the severity
of macular edema (ρ = 0.49, P = 0.029, ρ = 0.66, P = 0.003, and ρ = 0.61,
P = 0.006, respectively).
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macular edema.
Recently, the SCORE study [7] and the CRUISE study
[4] showed that intravitreal triamcinolone acetonide or
ranibizumab could improve visual acuity and macular
edema in CRVO patients. However, these studies did not
assess VEGF and inflammatory molecules in the aqueous
humor or vitreous fluid. Our findings suggest that it
might be better to measure VEGF and other molecules
before selecting a patient’s treatment. Such an approach
is supported by the report that aqueous samples are
useful for investigating the role of certain factors in
various diseases and for pharmacokinetic/pharmacody-
namic studies [19]. However, it is time-consuming and
expensive to measure these molecules in the aqueous
humor. The present study revealed that vitreous fluid
levels of VEGF, sICAM-1, and IL-6 were significantly
correlated with the aqueous flare value and with the
severity of macular edema in CRVO patients, and that
there was also a significant correlation between the flare
value and the severity of macular edema. Accordingly,
aqueous flare data could possibly be used to assess the
contribution of inflammation to macular edema associated
with CRVO. If a patient has a high aqueous flare value,
not only anti-VEGF therapy but also intravitreal injection
of triamcinolone acetonide could be considered. Triam-
cinolone acetonide may improve macular edema by
decreasing retinal capillary permeability via changes of
tight junctions [20], or it could inhibit the signaling
cascade involving VEGF and its receptor that increases
microvascular permeability [21,22]. Corticosteroids may
also prevent the production of various inflammatory
molecules [23-25] that promote leukocyte adhesion and
breakdown of the blood-retinal barrier, thus increasing
vascular permeability [26,27]. Taken together with such
reports, the present findings suggest that inflammatory
factors could be targeted to prevent an increase of
vascular permeability in CRVO patients with macular
edema, and measurement of the aqueous flare value
may help to select the best treatment strategy for CRVO-
associated macular edema. However, a randomized,
prospective, clinical trial comparing anti-VEGF therapy
with triamcinolone acetonide (and combined therapy)
would be required to assess efficacy for macular edema
associated with CRVO.
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We found a significantly higher aqueous flare value in
patients with CRVO than in those with MH. There was
also a significant correlation between the aqueous flare
value and the severity of macular edema in CRVO, and
vitreous fluid levels of VEGF, sICAM-1, and IL-6 were
significantly correlated with both the aqueous flare
value and the severity of macular edema in our CRVO
patients. To the best of our knowledge (based on a
Medline literature search), this is the first report about
the association of inflammatory factors and the aqueous
flare value with macular edema in CRVO patients. These
findings suggest that inflammatory factors like VEGF,
sICAM-1, and IL-6 increase vascular permeability and
disrupt the blood-aqueous barrier in CRVO patients
with macular edema.
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